Among the other diagnostic panels described, the EarlyCDT-Lung panel of 6 (p53, NY-ESO-1,CAGE, GBU4-5, Annexin I, and SOX2) or 7 (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4) autoantibodies released by Oncimmune Inc. showed high specificity and could detect elevated autoantibodies in 40% of LC (both non-small cell and small cell LC) independently of cancer stage (101–104, 108). This evidence concerns the gene TP53 and laryngotracheoesophageal cleft.